(Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating ...
Zacks Investment Research on MSN
Mirum completes enrollment & screening in liver disease studies
Mirum Pharmaceuticals MIRM announced that it has completed enrollment in the phase III AZURE-1 study, evaluating its pipeline ...
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
New research shows that deltaviruses can sneak into cells by hitchhiking inside other viruses, highlighting a previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results